fbpx

Gamida Cell to Present Preliminary Data from Ongoing Phase I NAM-NK Study at AACR International Meeting on Advances in Malignant Lymphoma

Gamida
Cell, a leading cellular and immune therapeutics company, today
announced that preliminary data from an ongoing phase I study from the
nicotinamide-based natural killer cell expansion, or NAM-NK, program
will be presented during the Inaugural AACR International Meeting on
Advances in Malignant Lymphoma, held June 22 – 26 in Boston,
Massachusetts.

Veronika Bachanova, M.D., Ph.D., hematologist/oncologist at the Blood
and Marrow Transplantation and Cellular Therapy Program of the
University of Minnesota, and lead investigator of the
investigator-sponsored phase I NAM-NK clinical study at the Masonic
Cancer Center, will present a poster of early patient outcomes from the
study in patients with refractory non-Hodgkin lymphoma and multiple
myeloma.

Title: Phase I study of nicotinamide-expanded related donor
Natural Killer (NK) cells for the treatment of relapsed/refractory CD20+
non-Hodgkin lymphoma (Abstract:
B05)Session: Poster Session B: Therapeutics and
Clinical Trials in Lymphoma 2Location: Salon F, Boston
Marriott Copley PlaceDate: Sunday June 24, 2018 11:45 AM –
1:45 PM

About NAM-NK

Gamida Cell applied the capabilities of its NAM-based cell expansion
technology to highly functional NK cells to develop NAM-NK, an innate
immunotherapy for the treatment of hematologic and solid tumors in
combination with SoC antibody therapies. NAM-NK addresses key
limitations of NK cells by increasing the cytotoxicity and in vivo retention
and proliferation in the bone marrow and lymphoid organs of NK cells
expanded in culture. NAM-NK is in phase I development (NCT03019666)
through an investigator-sponsored trial in patients with refractory
non-Hodgkin lymphoma and multiple myeloma.

About Gamida Cell

Gamida Cell is a clinical-stage biopharmaceutical company leveraging its
proprietary technology to develop cell therapies that are designed to
cure cancer and rare, serious hematologic diseases. The company is
developing a diverse pipeline based on its nicotinamide-, or NAM, -based
cell expansion technology, addressing limitations of current cell
therapies to provide new treatment alternatives for patients. To learn
more about Gamida Cell, including current clinical studies, please visit www.gamida-cell.com
and on Twitter,
LinkedIn
and Facebook.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180618005173/en/